American Society of Clinical Oncology Genitourinary Cancers Symposium 2025

180 $

Format : Video + PDF

Category: Video Medical

Description
Reviews (0)

The American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2025 is a premier event focused on the latest advancements in prostate, bladder, kidney, and other genitourinary cancers. It brings together oncologists, researchers, and healthcare professionals to discuss cutting-edge treatments, clinical trials, and emerging therapies.

Here are some key details:

Dates: February 13–15, 2025
Location: San Francisco, CA
Program Highlights:
- Prostate Cancer: Advances in radioligand therapies and androgen receptor pathway inhibitors.
- Bladder Cancer: Innovations in antibody drug conjugates and immunotherapy.
- Kidney Cancer: Biomarkers and new treatment strategies.
- Upper Tract Urothelial Carcinoma: Kidney-sparing approaches and perioperative therapies.

The American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2025 is tailored for professionals involved in genitourinary oncology, including:

Medical oncologists specializing in prostate, bladder, kidney, and other genitourinary cancers.
Urologists and radiation oncologists focused on multimodal treatment strategies.
Researchers and scientists presenting groundbreaking studies on biomarkers and emerging therapies.
Healthcare providers interested in the latest advancements in immunotherapy, targeted treatments, and surgical innovations.
Pharmaceutical and biotech professionals exploring novel drug developments.
Patient advocates and policy experts working to improve cancer care accessibility.

The symposium offers multidisciplinary perspectives, interactive sessions, and networking opportunities to enhance patient outcomes.

+ Topics:

Thursday, February 13, 2025

7:00 AM- 8:00 AM	Complimentary Continental Breakfast
7:00 AM- 6:45 AM	Exhibits Open
8:00 AM- 9:40 AM	Oral Abstract Session A: Prostate CancerKosj Yamoah, MD, PhD—Chair H. Lee Moffitt Cancer Center and Research InstituteChanning Judith Paller, MD—Chair The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Peter Hoskin, MD, FRCP, FRCR Welcome of the Day ABSTRACT 308: Gene signature predictor of dose-response to prostate radiation: Validation of PORTOS in phase III trials. First Author: Shuang Zhao, MD ABSTRACT 309: Radical prostatectomy (RP) versus radiotherapy (RT) in high-risk prostate cancer (HR-PCa): Emulated randomized comparison with individual patient data (IPD) from two phase III randomized trials (RCTs). First Author: Soumyajit Roy, MBBS Edwin Posadas, MD, FACP Cedars-Sinai Medical Center Discussion ABSTRACT LBA18: Final overall survival (OS) with talazoparib (TALA) + enzalutamide (ENZA) as first-line treatment in unselected patients with metastatic castration-resistant prostate cancer (mCRPC) in the phase 3 TALAPRO-2 trial. First Author: Neeraj Agarwal, MD, FASCO ABSTRACT 20: Which patients with metastatic hormone-sensitive prostate cancer (mHSPC) benefit more from androgen receptor pathway inhibitors (ARPIs)? STOPCAP meta-analyses of individual participant data (IPD). First Author: David John Fisher, MSc Tanya B. Dorff, MD City of Hope Comprehensive Cancer Center Discussion Panel Question and Answer
9:40 AM-10:10 AM	Break
10:10 AM-11:25 AM	Understanding Radioligand Therapies for Advanced Prostate CancerAngela Y Jia, MD, PhD—Chair University Hospitals Seidman Cancer Center and Case Western Reserve UniversityDevaki Shilpa Surasi, MBBS—Chair University of Texas at MD Anderson Cancer Center PSMA-Based Therapy in Advanced Disease: Touching on Combination Sequencing William Kevin Kelly, DO Thomas Jefferson University Hospital Beyond PSMA-Targeted Agents for Advanced Disease Danny Mena Cortes Nuclear Medicine World Seeing Is Believing: Radiographic Criteria to Assess Response ABSTRACT 17: Overall survival and quality of life with [¹⁷⁷Lu] Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in poor-risk, metastatic, castration-resistant prostate cancer in ENZA-p (ANZUP 1901). First Author: Louise Emmett, MD, FRACP, MBChB ABSTRACT 16: Association of baseline and on-treatment ctDNA fraction with clinical outcomes in patients with mCRPC in the PSMAfore study of ¹⁷⁷Lu-PSMA-617. First Author: Johann S. De Bono, MD, PhD, MB, FRCP Panel Question and Answer
11:25 AM-12:45 PM	Poster Session A: Prostate Cancer With Complimentary Boxed Lunch
11:25 AM-12:45 PM	Trials in Progress Poster Session A: Prostate Cancer With Complimentary Boxed Lunch
11:35 AM-12:35 PM	Trainee and Early-Career Networking LuncheonView the networking faculty list here
12:45 PM-2:00 PM	Case-Based Session: Management of Biochemical Recurrence After Radiation Therapy for Localized Prostate CancerMichael Cookson, MD, MMHC, FACS—Chair University of Oklahoma College of MedicineBarbara Jereczek-Fossa, MD—Chair IEO European Institute of Oncology IRCCS Michael Cookson, MD, MMHC, FACS University of Oklahoma College of Medicine Recurrence After Radiation Therapy: Evaluation, Management, and Outcomes Heather H. Cheng, MD, PhD University of Washington Medical Oncology Juanita Crook, FRCPC The University of British Columbia Radiation Oncology Thomas Polascik, MD Duke University Division of Urologic Surgery Urology (Ablative Focal) Ashley Ross, MD, PhD Northwestern University Feinberg School of Medicine Urology (Salvage Surgery) Alicia K. Morgans, MD, MPH, FASCO Dana-Farber Cancer Institute The Impact of Salvage Therapies: Functional Outcomes and Quality of Life Panel Question and Answer
2:15 PM-3:05 PM	KeynotePeter Hoskin, MD, FRCP, FRCR – Chair Mount Vernon Cancer Centre, University College London, and University of Manchester Introduction of Dr. DahutWilliam L. Dahut, MD American Cancer Society Creative Innovation: Driving Science to Improve Patient-Centered Care Question and Answer
3:05 PM- 3:30 PM	Break
3:30 PM- 4:45 PM	Case-Based Session: Evolving Landscape of the Management of Oligometastatic DiseaseKaren E. Hoffman, MD, MHSc, MPH—Chair The University of Texas MD Anderson Cancer CenterNicholas David James—Chair Institute of Cancer Research, The Royal Marsden Hospital NHS Foundation Trust ABSTRACT 15: World-wide oligometastatic prostate cancer (omPC) meta-analysis leveraging individual patient data (IPD) from randomized trials (WOLVERINE): An analysis from the X-MET collaboration. First Author: Chad Tang, MD, BS, MS Kenneth L. Gage, MD, PhD H. Lee Moffitt Cancer Center and Research Institute Radiology Brandon A. Mahal, MD University of Miami Radiation Oncology Kasmintan A. Schrader, PhD, MBBS BC Cancer Genetics Sandy Srinivas, MD Stanford School of Medicine Medical Oncology Panel Question and Answer
5:00 PM- 5:45 PM	Rapid Oral Abstract Session A: Prostate CancerMarjory Jolicoeur, MD, PhD, FRCPC—Chair Hôpital Charles-LeMoyneABSTRACT 310: Impact of testosterone recovery after androgen deprivation therapy on overall survival in patients with high-risk prostate cancer: Long-term data from a phase III trial. – 5 minutes First Author: Abdenour Nabid, MD ABSTRACT 311: Gut health and prostate cancer: The influence of a specific phytochemical-rich food capsule plus or minus a probiotic/prebiotic blend on symptoms and progression—A randomised, double-blind placebo-controlled trial. – 5 minutes First Author: Robert J. Thomas, MD ABSTRACT 312: A high omega-3, low omega-6 diet with fish oil for men with prostate cancer on active surveillance: The CAPFISH-3 randomized clinical trial. – 5 minutes First Author: William Aronson, MD ABSTRACT 21: Transdermal oestradiol (tE2) patches as androgen deprivation therapy (ADT): Efficacy and safety of combining with androgen receptor pathway inhibitors (ARPIs) in metastatic (M1) prostate cancer—Randomised comparison from the STAMPEDE trial platform. – 5 minutes First Author: Nicholas David James, PhD, FRCP, MBBS ABSTRACT 22: Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration resistant prostate cancer: A randomized phase II trial (GROUQ-PCS 9). – 5 minutes First Author: Tamim Niazi, MD ABSTRACT LBA138: Mevrometostat (PF-06821497), an enhancer of zeste homolog 2 (EZH2) inhibitor, in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC): A randomized dose-expansion study. – 5 minutes First Author: Michael Thomas Schweizer, MD Panel Question and Answer
5:45 PM-6:45 PM	Poster Session A (Continued) With Complimentary Wine and Cheese Reception
5:45 PM-6:45 PM	Trials in Progress Poster Session A (Continued) With Complimentary Wine and Cheese Reception
6:00 PM-6:45 PM	Poster Walks: Prostate CancerMarjory Jolicoeur, MD, PhD, FRCPC Hôpital Charles-LeMoyne Poster Walk LeaderChanning Judith Paller, MD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Poster Walk Leader
6:00 PM- 6:45 PM	Women’s Networking Reception

Friday, February 14, 2025

7:00 AM-8:10 AM	Complimentary Continental Breakfast
7:00 AM-5:45 PM	Exhibits Open
8:10 AM-9:45 AM	Oral Abstract Session B: Urothelial CarcinomaElizabeth A. Guancial, MD—Chair Florida Cancer Specialists & Research InstituteNicholas I. Simon, MD, MSc—Chair National Cancer Institute Andrea B Apolo, MD Welcome of the Day ABSTRACT 658: Adjuvant nivolumab (NIVO) vs placebo (PBO) for high-risk muscle-invasive urothelial carcinoma (MIUC): Additional efficacy outcomes including overall survival (OS) in patients (pts) with muscle-invasive bladder cancer (MIBC) from CheckMate 274. First Author: Matthew I. Milowsky, MD, FASCO ABSTRACT 659: Additional efficacy and safety outcomes and an exploratory analysis of the impact of pathological complete response (pCR) on long-term outcomes from NIAGARA. – 10 minutes First Author: Matthew D. Galsky, MD, FASCO Elizabeth R. Plimack, MD, FASCO, MS Fox Chase Cancer Center, Temple Health Discussion ABSTRACT 661: Safety and efficacy of neoadjuvant immunotherapy with durvalumab (MEDI 4736) in combination with neoadjuvant chemotherapy (gemcitabine/cisplatin or carboplatin) in patients with operable high-risk upper tract urothelial carcinoma. – 10 minutes First Author: Nadine Houede, MD ABSTRACT 665: Neoadjuvant treatment with disitamab vedotin plus perioperative toripalimab in patients with muscle-invasive bladder cancer (MIBC) with HER2 expression: Updated efficacy and safety results from the phase II RC48-C017 trial. – 10 minutes First Author: Xinan Sheng, MD Scot Anthony Niglio, MD, MS National Institutes of Health Division of Occupational Health and Safety Discussion Panel Question and Answer
9:45 AM-10:15 AM	Break
10:15 AM-11:30 AM	Case-Based Session: Non-Muscle Invasive Bladder Cancer: Exploring Therapies Beyond Bacillus Calmette-GuérinBrian Christopher Baumann, MD—Chair Springfield ClinicBogdana Schmidt, MD, MPH—Chair University of Utah The Changing World of Non-Muscle Invasive Bladder Cancer Case Presentation Girish S. Kulkarni, MD, PhD Department of Surgical Oncology, Princess Margaret Cancer Center, University Health Network Urology Mark Tyson, MPH Mayo Clinic Arizona Urology Tracy L Rose, MD University of North Carolina at Chapel Hill Medical Oncology Panel Question and Answer
11:30 AM-12:45 PM	Poster Session B: Urothelial Carcinoma With Complimentary Boxed Lunch
11:30 AM-12:45 PM	Trials in Progress Poster Session B: Urothelial Carcinoma With Complimentary Boxed Lunch
11:40 AM-12:35 PM	Breakout Session: Emerging Trends and Advances in Germ Cell TumorsAditya Bagrodia, MD—Chair University of California, San Diego HealthAnja Lorch, MD—Chair Universitätsspital Zürich Nabil Adra, MD Indiana University Health Melvin and Bren Simon Comprehensive Cancer Center High-Dose Chemotherapy in Testicular Cancer: Current Evidence and Clinical Indications Axel Heidenreich, MD University Hospital of Cologne Primary Retroperitoneal Lymph Node Dissection in Stage II Seminoma: Management Strategies and Current Controversies Darren R. Feldman, MD Memorial Sloan Kettering Cancer Center Landscape of New Trials and Targets in Refractory Germ Cell Tumors Panel Question and Answer
12:45 PM-2:00 PM	The ABCs of ADCs: Unleashing the Power of Antibody-Drug Conjugates in Advanced Bladder CancerKent William Mouw, MD, PhD—Chair Dana-Farber Cancer Institute, Brigham and Women’s HospitalBenjamin Garmezy, MD—Chair Sarah Cannon Research Institute Di Maria Jiang, MD, MSc, FRCPC Princess Margaret Hospital, University Health Network Targeting Bladder Cancer With Antibody Drug Conjugates Funda Meric-Bernstam, MD, FASCO University of Texas MD Anderson Cancer Center HER2 Antibody-Drug Conjugate Therapy: A New Frontier in Bladder Cancer Daniel Castellano, MD Servicio de Oncología Médica, Hospital Universitario 12 de Octubre Overcoming Challenges of Antibody-Drug Conjugate Toxicity in Bladder Cancer Terence W. Friedlander, MD University of California, San Francisco Medical Center Better Together? Exploring Novel Drug Combinations With Antibody-Drug Conjugates ABSTRACT 657: Nectin-4 targeted ADC, SHR-A2102, in patients with advanced or metastatic urothelial carcinoma: A phase 1 study. First Author: Bixia Tang, MD, PhD Panel Question and Answer
2:00 PM-2:30 PM	Break
2:30 PM-3:45 PM	Panning for Gold: The Role of ctDNA as a Biomarker for Bladder CancerBernadett Szabados, MBBS—Chair Barts Cancer CentreJoaquim Bellmunt, MD—Chair Dana-Farber Cancer Institute Roger Li, MD H. Lee Moffitt Cancer Center and Research Institute Capturing What You Cannot See: How Can ctDNA Be Used to Improve Clinical Staging for Upper Tract Disease? Alexander William Wyatt, PhD Vancouver Prostate Centre, University of British Columbia Evolution of Ctdna Detection with Next Generation Technology Nimira S. Alimohamed, FRCPC Arthur Child Comprehensive Cancer Centre, University of Calgary Potential Impact of ctDNA on Perioperative Management of Muscle-Invasive Bladder Cancer Gillian Vandekerkhove, PhD, MSc Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia Beneath the Surface: Unleashing the Potential of Ctdna across the Spectrum of Urothelial Carcinoma Panel Question and Answer
4:00 PM-4:45 PM	Rapid Oral Abstract Session B: Urothelial CarcinomaKatie S. Murray, DO, FACS, MS—Chair Department of Urology, NYU Langone HealthABSTRACT 662: A first-in-human phase 1 study of LY3866288 (LOXO-435), a potent, highly isoform-selective FGFR3 inhibitor (FGFR3i) in advanced solid tumors with FGFR3 alterations: Initial results from FORAGER-1. First Author: Gopa Iyer, MD ABSTRACT 663: Datopotamab deruxtecan (Dato-DXd) in locally advanced/metastatic urothelial cancer: Updated results from the phase 1 TROPIONPanTumor01 study. First Author: Funda Meric-Bernstam, MD, FASCO ABSTRACT 664: EV-302: Updated analysis from the phase 3 global study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC). First Author: Thomas Powles, MD, PhD, FCRP ABSTRACT 666: Clinically advanced urothelial bladder cancer (CAUBC) in young onset bladder cancer (YOUC) patients: A genomic landscape study. First Author: Alina Basnet, MD, MBBS ABSTRACT 667: A phase 1/2 trial of durvalumab plus intravesical gemcitabine and docetaxel in BCG-unresponsive non-muscle invasive bladder cancer patients (HCRN GU16-243: ADAPT-BLADDER Cohort 4). First Author: Noah M. Hahn, MD ABSTRACT 815: A phase 2 trial of risk enabled therapy after neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer (RETAIN-2). First Author: Pooja Ghatalia, MD Panel Question and Answer
4:45 PM-5:45 PM	Poster Session B (Continued) With Complimentary Wine and Cheese Reception
4:45 PM-5:45 PM	Trials in Progress Poster Session B (Continued) With Complimentary Wine and Cheese Reception
5:00 PM-5:45 PM	Poster Walks: Urothelial CarcinomaElias Chandran, FRACP, MBBS National Cancer Institute Poster Walk LeaderArmine Smith, MD Johns Hopkins University School of Medicine Poster Walk Leader

Saturday, February 15, 2025

7:00 AM-8:10 AM	Complimentary Continental Breakfast
7:10 AM-8:10 AM	Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers
7:10 AM-8:10 AM	Trials in Progress Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers
8:10 AM-9:45 AM	Oral Abstract Session C: Renal Cell CancerArpita Desai, MD—Chair University of California, San FranciscoDaniel Shapiro—Chair University of Wisconsin-Madison Todd Matthew Morgan, MD Welcome of the Day ABSTRACT 438: Cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC): Final results of COSMIC-313. First Author: Laurence Albiges, MD, PhD ABSTRACT 439: Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Final follow-up results from the CheckMate 9ER trial. First Author: Robert J. Motzer, MD ABSTRACT 440: KEYMAKER-U03 Substudy 03B: Pembrolizumab (pembro) and targeted therapy combinations for advanced clear cell renal cell carcinoma (ccRCC). First Author: Katy Beckermann, MD, PhD Tian Zhang, MD, MHS UT Southwestern University Discussion ABSTRACT 618: Prospective COTRIMS (Cologne trial of retroperitoneal lymphadectomy in metastatic seminoma) trial: Final results. First Author: Axel Heidenreich, MD Clint Cary, MD, MBA, MPH Indiana University Simon Comprehensive Cancer Center Discussion Panel Question and Answer
9:45 AM-10:15 AM	Break
10:15 AM-11:30 AM	Biomarkers and Adjuvant Therapy for Renal Cell Carcinoma: Current State and Future DirectionsShuchi Gulati, MD, MS, FACP—Chair University of California, Davis Comprehensive Cancer CenterAxel Bex, MD, PhD—Chair Royal Free London NHS Foundation Trust ABSTRACT 437: Evaluation of circulating kidney injury marker-1 (KIM-1) as a prognostic and predictive biomarker in advanced renal cell carcinoma (aRCC): Post-hoc analysis of CheckMate 214. First Author: Wenxin Xu, MD Simpa Samuel Salami, MD, MPH University of Michigan Biomarkers in Renal Cell Carcinoma: Dead End or Turning Point? Samra Turajlic, MD, PhD The Francis Crick Institute The Future of Biomarkers in Renal Cell Carcinoma Laurence Albiges, MD, PhD Gustave Roussy, Université Paris Saclay Adjuvant Therapy in Renal Cell Cancer: A Practical Guide Panel Question and Answer
11:30 AM-12:45 PM	Poster Session C (Continued) With Complimentary Boxed Lunch
11:30 AM-12:45 PM	Trials in Progress Poster Session C (Continued) With Complimentary Boxed Lunch
11:40 AM-12:35 PM	Women in Genitourinary Cancers Networking LuncheonView the networking faculty list here
11:45 AM-12:30 PM	Poster Walks: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral CancersBrittney Cotta, MD University of Texas MD Anderson Cancer Center Poster Walk LeaderShuchi Gulati, MD, FACP, MS UC Davis Comprehensive Cancer Center Poster Walk Leader
12:45 PM- 1:30 PM	Rapid Oral Abstract Session C: Renal Cell CancerBrittney Cotta, MD—Chair University of Texas MD Anderson Cancer CenterABSTRACT 441: Casdatifan (Cas) monotherapy in patients (pts) with previously treated clear cell renal cell carcinoma (ccRCC): Safety, efficacy and subgroup analysis across multiple doses from ARC-20, a phase 1 open-label study. First Author: Toni K. Choueiri, MD, FASCO ABSTRACT 442: Racial disparities in renal cell carcinoma histology and outcomes: Insights from the French Kidney Cancer Research Network (UroCCR-191). First Author: Xiaofan Lu, PhD ABSTRACT 443: Lenvatinib plus tislelizumab as first-line therapy for advanced fumarate hydratase-deficient renal cell carcinoma: A single-center, single-arm, phase II study. First Author: Wen Kong, PhD ABSTRACT 444: Final overall survival and new ctDNA analysis in MET-driven advanced papillary renal cancer (CALYPSO). First Author: Francesca Jackson-Spence, MBChB ABSTRACT 1: EPIC-A: Phase II trial of cemiplimab plus standard of care chemotherapy followed by maintenance cemiplimab in locally advanced or metastatic penile carcinoma. First Author: Amit Bahl, MD, FRCP, FRCR Panel Question and Answer
1:45 PM-3:00 PM	Case-Based Session: Failure of Immunotherapy in Renal Cell Cancer: What’s Next?Leslie K. Ballas, MD—Chair Cedars-Sinai Medical CenterKathryn Hacker Gessner, MD, PhD—Chair UNC School of Medicine Maria T. Bourlon, MD, MSc, FASCO Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán Medical Oncology Matthew T Campbell, MD, MS The University of Texas MD Anderson Cancer Center Medical Oncology Raquibul Hannan, MD, PhD University of Texas Southwestern Medical Center Radiation Oncology Viraj A. Master, MD, PhD Emory School of Medicine Urology Panel Question and Answer